Lee’s Pharm and Beijing Shenogen Pharma announced a second cancer partnership that involves Shenogen’s icaritin, a small molecule, TCM-derived treatment currently in China Phase III trials for hepatocellular carcinoma. In the latest joint effort, Lee’s Pharm will pair its PD-L1 candidate with icaritin. Lee’s in-licensed China rights to the PD-L1 molecule from San Diego’s Sorrento Therapeutics. One year ago, Lee’s and Shenogen agreed to co-develop a combination of Lee’s Pexa-Vec, an oncolytic virus intended for HCC, and icaritin.
Source: China Biotoday
